Caribou Biosciences Inc. (CRBU)
Caribou Biosciences Statistics
Share Statistics
Caribou Biosciences has 93M shares outstanding. The number of shares has increased by 2.97% in one year.
| Shares Outstanding | 93M |
| Shares Change (YoY) | 2.97% |
| Shares Change (QoQ) | 2.71% |
| Owned by Institutions (%) | 64.42% |
| Shares Floating | 80.81M |
| Failed to Deliver (FTD) Shares | 15.07K |
| FTD / Avg. Volume | 1.34% |
Short Selling Information
The latest short interest is 9.89M, so 10.63% of the outstanding shares have been sold short.
| Short Interest | 9.89M |
| Short % of Shares Out | 10.63% |
| Short % of Float | 11.13% |
| Short Ratio (days to cover) | 9.5 |
Valuation Ratios
The PE ratio is -0.96 and the forward PE ratio is -0.51. Caribou Biosciences's PEG ratio is -0.05.
| PE Ratio | -0.96 |
| Forward PE | -0.51 |
| PS Ratio | 14.37 |
| Forward PS | 0 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -1 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Caribou Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.1.
| Current Ratio | 7.16 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.16 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $67.99K |
| Profits Per Employee | $-1.01M |
| Employee Count | 147 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9K |
| Effective Tax Rate | 0.01% |
Stock Price Statistics
The stock price has increased by -79.25% in the last 52 weeks. The beta is 2.36, so Caribou Biosciences's price volatility has been higher than the market average.
| Beta | 2.36 |
| 52-Week Price Change | -79.25% |
| 50-Day Moving Average | 1.01 |
| 200-Day Moving Average | 1.71 |
| Relative Strength Index (RSI) | 40.55 |
| Average Volume (20 Days) | 1.12M |
Income Statement
In the last 12 months, Caribou Biosciences had revenue of 9.99M and earned -149.1M in profits. Earnings per share was -1.65.
| Revenue | 9.99M |
| Gross Profit | 9.99M |
| Operating Income | -166.62M |
| Net Income | -149.1M |
| EBITDA | -166.62M |
| EBIT | -166.62M |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has 16.29M in cash and 26.49M in debt, giving a net cash position of -10.19M.
| Cash & Cash Equivalents | 16.29M |
| Total Debt | 26.49M |
| Net Cash | -10.19M |
| Retained Earnings | -448.39M |
| Total Assets | 313.31M |
| Working Capital | 188.73M |
Cash Flow
In the last 12 months, operating cash flow was -138.2M and capital expenditures -4.88M, giving a free cash flow of -143.08M.
| Operating Cash Flow | -138.2M |
| Capital Expenditures | -4.88M |
| Free Cash Flow | -143.08M |
| FCF Per Share | -1.58 |
Margins
Gross margin is 100%, with operating and profit margins of -1667.16% and -1491.95%.
| Gross Margin | 100% |
| Operating Margin | -1667.16% |
| Pretax Margin | -1492.04% |
| Profit Margin | -1491.95% |
| EBITDA Margin | -1667.16% |
| EBIT Margin | -1667.16% |
| FCF Margin | -1431.66% |
Dividends & Yields
CRBU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRBU is $11, which is 1328.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 1328.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -2.23 |
| Piotroski F-Score | 2 |